Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia
Transplantation of dopamine- (DA-) rich foetal ventral mesencephalic cells emerged as a promising therapy for Parkinson’s disease (PD), as it allowed significant improvement of motor symptoms in several PD patients in open-label studies. However, double-blind clinical trials have been largely disapp...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2015/563820 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309368540987392 |
|---|---|
| author | Elisabetta Tronci Camino Fidalgo Manolo Carta |
| author_facet | Elisabetta Tronci Camino Fidalgo Manolo Carta |
| author_sort | Elisabetta Tronci |
| collection | DOAJ |
| description | Transplantation of dopamine- (DA-) rich foetal ventral mesencephalic cells emerged as a promising therapy for Parkinson’s disease (PD), as it allowed significant improvement of motor symptoms in several PD patients in open-label studies. However, double-blind clinical trials have been largely disappointing. The general agreement in the field is that the lack of standardization of tissue collection and preparation, together with the absence of postsurgical immunosuppression, played a key role in the failure of these studies. Moreover, a further complication that emerged in previous studies is the appearance of the so-called graft-induced dyskinesia (GID), in a subset of grafted patients, which resembles dyskinesia induced by L-DOPA but in the absence of medication. Preclinical evidence pointed to the serotonin neurons as possible players in the appearance of GID. In agreement, clinical investigations have shown that grafted tissue may contain a large number of serotonin neurons, in the order of half of the DA cells; moreover, the serotonin 5-HT1A receptor agonist buspirone has been found to produce significant dampening of GID in grafted patients. In this paper, we will review the recent preclinical and clinical studies focusing on cell transplantation for PD and on the mechanisms underlying GID. |
| format | Article |
| id | doaj-art-113d41db1bd74b67942fd48698bd98b8 |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-113d41db1bd74b67942fd48698bd98b82025-08-20T03:54:11ZengWileyParkinson's Disease2090-80832042-00802015-01-01201510.1155/2015/563820563820Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced DyskinesiaElisabetta Tronci0Camino Fidalgo1Manolo Carta2Department of Biomedical Sciences, Section of Physiology, Cagliari University, SS 554, km 4.500, 09042 Monserrato, ItalyDepartment of Biomedical Sciences, Section of Physiology, Cagliari University, SS 554, km 4.500, 09042 Monserrato, ItalyDepartment of Biomedical Sciences, Section of Physiology, Cagliari University, SS 554, km 4.500, 09042 Monserrato, ItalyTransplantation of dopamine- (DA-) rich foetal ventral mesencephalic cells emerged as a promising therapy for Parkinson’s disease (PD), as it allowed significant improvement of motor symptoms in several PD patients in open-label studies. However, double-blind clinical trials have been largely disappointing. The general agreement in the field is that the lack of standardization of tissue collection and preparation, together with the absence of postsurgical immunosuppression, played a key role in the failure of these studies. Moreover, a further complication that emerged in previous studies is the appearance of the so-called graft-induced dyskinesia (GID), in a subset of grafted patients, which resembles dyskinesia induced by L-DOPA but in the absence of medication. Preclinical evidence pointed to the serotonin neurons as possible players in the appearance of GID. In agreement, clinical investigations have shown that grafted tissue may contain a large number of serotonin neurons, in the order of half of the DA cells; moreover, the serotonin 5-HT1A receptor agonist buspirone has been found to produce significant dampening of GID in grafted patients. In this paper, we will review the recent preclinical and clinical studies focusing on cell transplantation for PD and on the mechanisms underlying GID.http://dx.doi.org/10.1155/2015/563820 |
| spellingShingle | Elisabetta Tronci Camino Fidalgo Manolo Carta Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia Parkinson's Disease |
| title | Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia |
| title_full | Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia |
| title_fullStr | Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia |
| title_full_unstemmed | Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia |
| title_short | Foetal Cell Transplantation for Parkinson’s Disease: Focus on Graft-Induced Dyskinesia |
| title_sort | foetal cell transplantation for parkinson s disease focus on graft induced dyskinesia |
| url | http://dx.doi.org/10.1155/2015/563820 |
| work_keys_str_mv | AT elisabettatronci foetalcelltransplantationforparkinsonsdiseasefocusongraftinduceddyskinesia AT caminofidalgo foetalcelltransplantationforparkinsonsdiseasefocusongraftinduceddyskinesia AT manolocarta foetalcelltransplantationforparkinsonsdiseasefocusongraftinduceddyskinesia |